StockData
Royalty Pharma plc logo

Royalty Pharma plc (RPRX) stock

RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3049% above fair value
$68.53−0.78 (-1.13%)

Close on Nov 16, 2026Market cap $39.40BP/E 38.9Yield –

Royalty Pharma total assets

Total assets on the balance sheet at the end of each period.

Royalty Pharma's total assets was $19.82B at Jun 30, 2026. For fiscal 2025 it was $19.62B, up 7.7% from the year before. The highest annual figure on record is $19.62B in fiscal 2025.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$19.62B+7.7%
FY2024Dec 31, 2024$18.22B+11.2%
FY2023Dec 31, 2023$16.38B-2.6%
FY2022Dec 31, 2022$16.81B-4.0%
FY2021Dec 31, 2021$17.52B+9.3%
FY2020Dec 31, 2020$16.02B+28.7%
FY2019Dec 31, 2019$12.45B–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$19.82B+8.2%
Q1 FY2026Mar 31, 2026$19.82B+12.5%
Q4 FY2025Dec 31, 2025$19.62B+7.7%
Q3 FY2025Sep 30, 2025$19.35B+7.2%
Q2 FY2025Jun 30, 2025$18.32B+3.8%
Q1 FY2025Mar 31, 2025$17.61B+9.2%
Q4 FY2024Dec 31, 2024$18.22B+11.2%
Q3 FY2024Sep 30, 2024$18.04B+13.8%
Q2 FY2024Jun 30, 2024$17.66B+3.1%
Q1 FY2024Mar 31, 2024$16.13B-5.5%
Q4 FY2023Dec 31, 2023$16.38B-2.6%
Q3 FY2023Sep 30, 2023$15.86B-10.3%
Q2 FY2023Jun 30, 2023$17.12B-3.5%
Q1 FY2023Mar 31, 2023$17.07B-1.8%
Q4 FY2022Dec 31, 2022$16.81B-4.0%
Q3 FY2022Sep 30, 2022$17.67B-0.3%
Q2 FY2022Jun 30, 2022$17.74B+7.4%
Q1 FY2022Mar 31, 2022$17.38B+9.2%
Q4 FY2021Dec 31, 2021$17.52B+9.3%
Q3 FY2021Sep 30, 2021$17.73B+10.9%
Q2 FY2021Jun 30, 2021$16.51B+5.3%
Q1 FY2021Mar 31, 2021$15.91B+27.8%
Q4 FY2020Dec 31, 2020$16.02B–
Q3 FY2020Sep 30, 2020$15.99B–
Q2 FY2020Jun 30, 2020$15.69B–
Q4 FY2019Dec 31, 2019$12.45B–

More Royalty Pharma figures

See a number that looks wrong?